These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24062388)

  • 1. Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission.
    Mawad R; Gooley TA; Sandhu V; Lionberger J; Scott B; Sandmaier BM; O'Donnell P; Becker PS; Petersdorf S; Dorcy KS; Hendrie P; Sorror ML; Walter RB; Deeg HJ; Appelbaum FR; Estey EH; Pagel JM
    J Clin Oncol; 2013 Nov; 31(31):3883-8. PubMed ID: 24062388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2.
    Michelis FV; Messner HA; Atenafu EG; McGillis L; Lambie A; Uhm J; Alam N; Seftel MD; Gupta V; Kuruvilla J; Lipton JH; Kim DD
    Bone Marrow Transplant; 2015 Nov; 50(11):1405-10. PubMed ID: 26168067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
    Heinicke T; Krahl R; Kahl C; Cross M; Scholl S; Wolf HH; Hähling D; Hegenbart U; Peter N; Schulze A; Florschütz A; Schmidt V; Reifenrath K; Zojer N; Junghanss C; Sayer HG; Maschmeyer G; Späth C; Hochhaus A; Fischer T; Al-Ali HK; Niederwieser D
    Ann Hematol; 2021 Sep; 100(9):2387-2398. PubMed ID: 34232360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.
    Weisdorf DJ; Millard HR; Horowitz MM; Hyare PS; Champlin R; Ho V; Mielcarek M; Rezvani A; Stockerl-Goldstein K; Khoury HJ; De Lima M; Saber W; Sandmaier B; Zhang MJ; Eapen M
    Cancer; 2017 Jun; 123(11):2025-2034. PubMed ID: 28117884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
    Bornhäuser M; Schliemann C; Schetelig J; Röllig C; Kramer M; Glass B; Platzbecker U; Burchert A; Hänel M; Müller LP; Klein S; Bug G; Beelen D; Rösler W; Schäfer-Eckart K; Schmid C; Jost E; Lenz G; Tischer J; Spiekermann K; Pfirrmann M; Serve H; Stölzel F; Alakel N; Middeke JM; Thiede C; Ehninger G; Berdel WE; Stelljes M
    JAMA Oncol; 2023 Apr; 9(4):519-526. PubMed ID: 36757706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.
    Pagel JM; Othus M; Garcia-Manero G; Fang M; Radich JP; Rizzieri DA; Marcucci G; Strickland SA; Litzow MR; Savoie ML; Spellman SR; Confer DL; Chell JW; Brown M; Medeiros BC; Sekeres MA; Lin TL; Uy GL; Powell BL; Bayer RL; Larson RA; Stone RM; Claxton D; Essell J; Luger SM; Mohan SR; Moseley A; Erba HP; Appelbaum FR
    JCO Oncol Pract; 2020 Jun; 16(6):e464-e475. PubMed ID: 32048933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission.
    Usuki K; Kurosawa S; Uchida N; Yakushiji K; Waki F; Matsuishi E; Kagawa K; Furukawa T; Maeda Y; Shimoyama M; Ago H; Yamano Y; Yano S; Fujishima N; Takamatsu Y; Eto T; Hidaka M; Matsuoka H; Fukuda T
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):444-51. PubMed ID: 22999942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission.
    Kurosawa S; Yamaguchi T; Miyawaki S; Uchida N; Kanamori H; Usuki K; Yamashita T; Watanabe M; Yakushiji K; Yano S; Nawa Y; Taguchi J; Takeuchi J; Tomiyama J; Nakamura Y; Miura I; Kanda Y; Takaue Y; Fukuda T
    Blood; 2011 Feb; 117(7):2113-20. PubMed ID: 21106987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission.
    Yano S; Yokoyama H; Yanada M; Mori J; Aoki J; Ohashi K; Kanomori H; Ozawa Y; Sawa M; Nakamae H; Eto T; Ohta S; Tanaka J; Ichinohe T; Atsuta Y; Takami A
    Bone Marrow Transplant; 2019 Dec; 54(12):2004-2012. PubMed ID: 31152148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
    Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
    Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
    Rashidi A; Linden MA; DeFor TE; Warlick E; Bejanyan N; Yohe S; Weisdorf DJ; Ustun C
    Am J Hematol; 2017 Oct; 92(10):1032-1036. PubMed ID: 28646534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.
    Warlick ED; Paulson K; Brazauskas R; Zhong X; Miller AM; Camitta BM; George B; Savani BN; Ustun C; Marks DI; Waller EK; Baron F; Freytes CO; Socie G; Akpek G; Schouten HC; Lazarus HM; Horwitz EM; Koreth J; Cahn JY; Bornhauser M; Seftel M; Cairo MS; Laughlin MJ; Sabloff M; Ringdén O; Gale RP; Kamble RT; Vij R; Gergis U; Mathews V; Saber W; Chen YB; Liesveld JL; Cutler CS; Ghobadi A; Uy GL; Eapen M; Weisdorf DJ; Litzow MR
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):202-8. PubMed ID: 24184335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics.
    Yamasaki S; Yoshimoto G; Ogawa R; Aoki K; Higuchi M; Harada N; Arima F; Kondo S; Matubara F; Takahashi T; Uike N; Miyamoto T; Okamura S; Akashi K;
    Ann Hematol; 2015 Jul; 94(7):1159-65. PubMed ID: 25704584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.
    Vu K; Manjappa S; DiPersio JF; Gao F; Westervelt P; Vij R; Stockerl-Goldstein KE; Uy GL; Abboud CN; Schroeder MA; Fehniger TA; Cashen AF; Romee R
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1425-30. PubMed ID: 25840336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Passweg JR; Labopin M; Christopeit M; Cornelissen J; Pabst T; Socié G; Russel N; Yakoub-Agha I; Blaise D; Gedde-Dahl T; Labussière-Wallet H; Malladi R; Forcade E; Maury S; Polge E; Lanza F; Gorin NC; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):659-664. PubMed ID: 31759159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years.
    Bazarbachi A; Schmid C; Labopin M; Beelen D; Wolfgang Blau I; Potter V; Niittyvuopio R; Socié G; Blaise D; Sanz J; Ciceri F; Abou Dalle I; Spyridonidis A; Bug G; Esteve J; Savani BN; Nagler A; Mohty M
    Clin Cancer Res; 2020 Dec; 26(24):6475-6482. PubMed ID: 32988970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission.
    Lv M; Wang Y; Chang YJ; Zhang XH; Xu LP; Jiang Q; Jiang H; Lu J; Chen H; Han W; Wang FR; Wang JZ; Chen Y; Yan CH; Zhang YY; Sun YQ; Mo XD; Zhu HH; Jia JS; Zhao T; Wang J; Liu KY; Huang XJ
    Clin Cancer Res; 2019 Mar; 25(6):1737-1748. PubMed ID: 30478089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.